A randomized controlled trial was conducted to assess the efficacy and safety of baclofen (Baclofen 20 mg) in the treatment of chronic pain in patients with spinal cord injuries. In this study, a total of 60 patients with chronic pain (acute post-traumatic pain, spinal cord injury, or other spinal cord injury) were treated in three groups. Group A received a single dose of baclofen, group B received a single dose of 10 mg BID, and group C received baclofen 20 mg alone. Group D received the same dose of baclofen in a placebo group. Groups D and B were administered to patients after standard therapy. The primary endpoint of the study was change in the pain scores from baseline to 12 weeks. There were no statistically significant differences between groups for the primary and secondary endpoint, the primary endpoints, or the secondary endpoints. No statistically significant difference was found for the secondary endpoints. In conclusion, baclofen 20 mg alone was effective for chronic pain in patients with spinal cord injury. However, the primary endpoints and the secondary endpoints were not significantly different between groups. It is important for patients with spinal cord injury to take appropriate medical and spinal therapy.
Spinal Cord injuries (SCI) are a common medical problem that can cause symptoms in spinal cord injury patients, including pain and stiffness. Baclofen (BID), a common medication used to treat SCI, has gained popularity because of its effectiveness in treating pain. This drug is commonly prescribed for pain, muscle spasms, and fever. It has been approved for several indications:Pain Management-Muscle Spasm–Muscle VaginosisPainPain ControlPain TreatmentPain Relapse PreventionPain Relief. The treatment of SCI is crucial in the treatment of chronic pain. Baclofen is an opioid analgesic that has been approved for the treatment of SCI in a number of clinical trials:
The treatment of SCI, however, has been a topic of debate, mainly because of the potential adverse effects of the drugs.
Pain is a common and distressing symptom in both sexes, especially in women. Despite the significant prevalence of neuropathic pain, there is little research examining the efficacy of Baclofen or Gabapentin in treating this condition. The aim of this study was to compare the effectiveness and tolerability of baclofen and Gabapentin.
This was a retrospective study of patients with postherpetic neuralgia, a chronic neurological disorder, who were treated with baclofen for 10 years. A total of 822 patients were included, with a median age of 63 years (range: 26–85 years). The median duration of treatment was 7.1 years, ranging from 2 months to 10 years. Patients received Gabapentin or baclofen at a dose of 10 mg/kg every 12 hours for 5 days. The mean International Index of Erectile Function (IIEF) score was 5 (range: 2–11). The median I-EF score was 17 (range: 5–43).
Gabapentin was the most effective treatment for patients with postherpetic neuralgia (n=440) compared with baclofen (n=440), followed by baclofen (n=440) and placebo (n=220) in the total sample (see Fig. ).
Fig. 1Boxed boxplot of the results for baclofen and Gabapentin in the total sample. The first five boxes are standard boxes. Box 1 is the box of the largest sample size. The last box represents the box of the smallest sample size. The X-axis indicates the treatment time (h). The number of patients with the largest sample size is 1, and the number of patients with the smallest sample size is 0.
2Boxed boxplot of the results for baclofen and Gabapentin in the total sample (n=440).
The sample included 515 patients with postherpetic neuralgia. In this sample, patients with postherpetic neuralgia were treated with baclofen or Gabapentin. The mean treatment time was 7.1 years. The sample size was distributed evenly across the age range (range: 2–10 years). The mean I-EF score was 17 (range: 5–43).
Table 2 Treatment outcomesThe sample included 662 patients with postherpetic neuralgia who received baclofen or Gabapentin, and were treated with baclofen. The mean duration of treatment was 2.5 years. The mean I-EF score was 16 (range: 5–43).
The results of this study revealed that baclofen was more effective than Gabapentin in the treatment of postherpetic neuralgia. There was no significant difference between the treatment groups in terms of mean I-EF score, the percentage of patients with I-EF score ≥17, and the percentage of patients with I-EF score ≥44. In addition, the mean duration of treatment was 2.5 years. The mean I-EF score was 17 (range: 5–43) for baclofen and Gabapentin, and the percentage of patients with I-EF score ≥17 was more than 20. The mean I-EF score was not significantly different between the groups in terms of the percentage of patients with I-EF score ≥17, or the percentage of patients with I-EF score ≥44.
Medically reviewed by Jessica Swirble, PharmDLast updated on April 18, 2025
Drug Information| | |
In the treatment of spasticity, Baclofen is used to treat the following conditions:Breathing difficulty in freedom of movement, uncontrolled muscle tone, or involuntary muscle contraction-
It works by relaxing the muscles found in the airways and allows the air passages to open up which allows easier breathing
Baclofen may also be used to treat a certain type of muscle spasms, which are caused by other conditions
CBT is a behavioral treatment that is often used in the treatment of problems with attention, memory, and impulse control.
The treatment includes being shown to help improve behavior, but many people do not have success with this treatment.
Side Effects
The most common side effects are sedation, dry mouth, dry skin, headache, constipation, weight gain, stomach pain, and nausea.
The serious side effects include agitation, loss of coordination, confusion, increased sensitivity to light, and seizures.
The less common side effects include difficulty sleeping, loss of appetite, dry cough, abnormal bleeding or bruising, and sweating.
The treatment may also cause liver problems and changes in the balance of blood cells.
The treatment may also cause blurred vision, drowsiness, and nausea.
The treatment may only be done under the supervision of a healthcare professional.
The serious side effects are moderate to severe and may includeinsomnia, rapid heartbeat, increased thirst, abnormal muscle tone, seizures, and drowsiness.
The treatment may only be done with a patient's permission.
Baclofen Tablets 20 mg by Teva is a muscle relaxer and an antispastic agent. Baclofen is used to treat muscle symptoms caused by multiple sclerosis, including spasm, pain, and stiffness. Baclofen may also be used for purposes not listed in this medication guide.
Each tablet, for oral administration, contains 20 mg baclofen, USP. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate.
Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases.
Baclofen tablets USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.
The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions.
Brand: Teva PharmaceuticalsSize: 100 Tablets (20 mg)Strength: 20 mgNDC: #: 1745-6276-59
Buy Baclofen Tablets 20 mg by Teva
Manufacturer: TevaStrength: 20 mgNDC: #: 1745-6276-59
Read this Label Before taking this medicine, tell your doctor and pharmacist which medical conditions, drugs, and supplements you are taking. Also test your medicine by tell your doctor/medicine. This comes in two forms, film-coated and liquid form.Baclofen, the active ingredient in the medication, belongs to a class of medications known as muscle relaxants. It works by enhancing neurotransmitters in the brain. It is used to treat multiple sclerosis, spasticity caused by spinal cord injuries, cerebral palsy, and Parkinson's disease.
This medicine may cause your nervous system to stop working suddenly. Tell your doctor if this happens more suddenly than you should think about it.
Baclofen tablets, film-coated tablets, and liquid Baclofen tablets USP are used for the relief of symptoms caused by multiple sclerosis, including pain, pain, and stiffness, resulting from spinal cord injuries, cerebral palsy, and Parkinson's disease.
Baclofen tablets, film-coated tablets, and Baclofen tablets USP are used for the treatment of symptoms of spasticity resulting from multiple sclerosis, including flexor spasms and concomitant pain, clonus, and muscular rigidity.
Baclofen tablets USP are indicated for the treatment of symptoms of spasm caused by spinal cord injuries, cerebral palsy, and Parkinson's disease. It may also be used for purposes not listed in this medication guide.
Baclofen tablets USP are used for the treatment of pain, clonus, and muscular rigidity caused by multiple sclerosis.
This medicine is estimated at USD 30.27 billion (2019-20). This is approximately 17% of the global market for prescription medicines, which is approximately $2.9 billion of which is related to theamus, spasms, and skeletal muscle spasms.
The global market for Baclofen Tablets 20 mg by Teva is approximately $1.2 billion (2019-20).
Baclofen Tablets USP, film-coated tablets
If you are taking this medicine and are experiencing the following symptoms, you may have the following questions:
Q: What is the best brand for this medicine?
A:The most appropriate brand for this medicine is Teva, because Teva has a strong reputation for quality medicines. It is often the preferred brand for many products, and its manufacturing process is known as a controlled substance.
The American Psychiatric Association has urged physicians to avoid prescribing Baclofen as it may cause side effects in patients with Parkinson's disease. Baclofen is used to treat muscle spasms and painful muscle spasms in people with Parkinson's disease. In one study, the authors of the.
Baclofen is also sometimes used to treat anxiety, depression and other symptoms of anxiety disorders. The FDA recently approved the use of Baclofen as a treatment for anxiety, depression and other symptoms of depression in people with Parkinson's disease.
The use of Baclofen for anxiety, depression and other symptoms of anxiety disorders has been controversial and not generally recommended for use in people with Parkinson's disease. The FDA has also required the manufacturer of Baclofen to submit a warning about the potential risk of serious side effects in the form of a prescription. A study of more than 600 people with Parkinson's disease showed that patients taking the drug were also at an increased risk of developing serious side effects.
The Food and Drug Administration, the maker of the drug, says that the drug was found to be unsafe in the study.
In fact, patients taking Baclofen should stop taking it and inform their doctors of their risk. Patients should also discuss their mental health and medical conditions with their doctors before starting Baclofen, the FDA says.
The FDA has warned that taking Baclofen may increase the risk of suicidal thoughts in some people. The FDA has also warned that patients should not take Baclofen if they have serious heart problems. The FDA also warned that the use of Baclofen in people with Parkinson's disease should be carefully monitored.
Baclofen has been associated with a range of side effects, including muscle cramps, dizziness and headaches. Baclofen may also be associated with other problems such as muscle spasms, pain, sleepiness and constipation.
Baclofen is not approved for the treatment of Parkinson's disease, but it is not a drug used to treat the disease. The FDA has issued a warning about the use of Baclofen in patients with Parkinson's disease. The FDA has also issued a warning about the risk of a rare but serious side effect in people with Parkinson's disease.
The FDA also recently issued a warning that Baclofen may increase the risk of a rare but serious side effect in people with Parkinson's disease. The FDA also has directed the manufacturer of Baclofen to submit a warning about the risk of a rare but serious side effect in people with Parkinson's disease.
The FDA also has issued a warning about the risk of side effects in people with Parkinson's disease. The FDA has also directed the manufacturer of Baclofen to submit a warning about the risk of a rare but serious side effect in people with Parkinson's disease.
The FDA has directed the manufacturer of Baclofen to submit a warning about the risk of a rare but serious side effect in people with Parkinson's disease.The FDA has issued a warning about the risk of side effects in people with Parkinson's disease.
The FDA has issued a warning about the risk of a rare but serious side effect in people with Parkinson's disease.
Baclofen has been associated with a range of side effects, including muscle cramps, dizziness, headaches and insomnia. Baclofen can interact with other drugs, blood thinners and blood pressure medications, and can increase the risk of serious side effects in people with Parkinson's disease. In addition, the FDA has directed that Baclofen be prescribed only for patients with Parkinson's disease.
Stade de France Pharmacy